RPRX Stock Analysis: Buy, Sell, or Hold?
RPRX - Royalty Pharma plc Class A Ordinary Shares
$55.35
1.78 (3.32%)
▲
5d:
+1.99%
30d:
+3.36%
90d:
+21.35%
HOLD
MODERATE Confidence
Analysis Updated: Jun 23, 2026 12:00 AM ET
Earnings: Aug 05, 2026
Smart Money Accumulation
None View Scanner →
Strength: 4.6/10
Get Alerted When RPRX Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: RPRX is fairly valued with market pricing in 4.6% annual growth. Fine to hold or accumulate slowly on dips.
📊 HOLD: RPRX is fairly valued with market pricing in 4.6% annual growth. Fine to hold or accumulate slowly on dips.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$67.18
Based on 6.8% avg growth
INTRINSIC VALUE TODAY
$41.72
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 8.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: RPRX is currently trading at $55.35, which is considered extended relative to its 30-day fair value range of $53.25 to $55.28. From a valuation perspective, the stock is trading at a premium (Forward PE: 9.9) compared to its historical average (8.6). At these levels, the market is pricing in 4.6% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $56.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, RPRX is in a strong uptrend. The price is approaching resistance at $56.23. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation. The stock is showing strong short-term momentum, up 3.3% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$53.25 -
$55.28
Company Quality Score
60/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
51.9%
Protect Your Profits
Holding RPRX? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BULLISH: Strong upward momentum (+3.3%)
- NEUTRAL: Near Wall St target ($59.25)
- NEUTRAL: Market pricing in 4.6% annual earnings growth - fairly valued
Trading Range Analysis
30-Day Trading Range
$53.25 -
$55.28
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$51.15
Resistance Level
$56.23
Current Trend
Strong Uptrend
Technical data as of
Jun 23, 2026
Fundamental Context
Forward P/E (Next Year Est.)
9.86
Wall Street Target
$59.25
(+7.0%)
Revenue Growth (YoY)
11.0%
Earnings Growth (YoY)
23.2%
Profit Margin
33.9%
Valuation Premium vs History
+4.6% premium
PE vs Historical
9.9 vs 8.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+4.6%
(market-implied from PE analysis)
1-Year Target
$57.90
(+5%)
2-Year Target
$60.56
(+9%)
3-Year Target
$63.35
(+14%)
3-Yr Target (if PE normalizes)
(PE: 10→9)
PE COMPRESSION
$55.25
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 21.8, Growth: 9.7%)
$161.43
(+192%)
Base:
(SPY PE: 9.9, Growth: 9.7%)
$73.07
(+32%)
Bear:
(PE: 8.4, Growth: 9.7%)
$62.11
(+12%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (28x PE), but valuation improves significantly next year (10x PE) as earnings recover.
Trailing PE: 27.87 | Current EPS (TTM): $1.90
Bull Case
$116.51
(+111%)
Analyst growth 100.0%, PE expands to 30.7
Base Case
$105.92
(+91%)
Market implied 100.0%, PE stable at 27.9
Bear Case
$36.01
(-35%)
Severe decline -20.0%, PE contracts to 23.7
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: June 24, 2026 2:33 AM ET
Data refreshes hourly during market hours. Next update: 3:33 AM
Data refreshes hourly during market hours. Next update: 3:33 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is RPRX showing a specific setup today?
Insider Activity (6 Months)
0
Buys
12
Sells
Net
INSIDERS SELLING
Recent Transactions
Terrance P Coyne
SELL
34791 shares
2026-04-01
Terrance P Coyne
SELL
34791 shares
2026-03-23
Terrance P Coyne
SELL
34791 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
REGN
Regeneron Pharmaceutical… |
STRONG BUY
25 analysts |
$833 | 67 BUY |
|
XENE
Xenon Pharmaceuticals Inc |
STRONG BUY
19 analysts |
$81 | 67 BUY |
|
IONS
Ionis Pharmaceuticals Inc |
BUY
26 analysts |
$105 | 64 BUY |
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$34 | 61 BUY |
|
MLTX
MoonLake Immunotherapeut… |
STRONG BUY
16 analysts |
$28 | 65 BUY |
Advanced RPRX Option Strategies
Professional options setups generated by AI based on today's RPRX price and gamma walls.
